Tweets
#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Are we asking women with IPAF about family planning?
Abstract #0944 #ACR22 @RheumNow
🫁 31 women
🤰83% had RF for adverse pregnancy outcomes
👼1/3 women had family plan. or birth control talks with pulm. docs
✋>50% women who saw a rheumatologist discussed these topics
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
#abst2109 #ACR22 @RheumNow GO-VIBRANT bio-naïve pts w/active PsA Rx w/IV GLM tend respond slower in all domains if ⬆️ age, HAQ-DI score, and spinal pain; smoking gives w/lower odds of HAQ-DI ≤0.5 at W52. minimal SJC& ⬇️enthesitis achieved significantly faster than TJC, HAQ-DI https://t.co/qqmjEAq3Cd
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
#ACR22 Abstr#L08 Is Evusheld effective in the first 6 mths of therapy in #COVID Omicron era? A cohort study of 157 RMD patients who were fully vaccinated reported 24 (15%) breakthrough infection; only 2 (1%) required hospitalisation. COVID occurred ~3mths post-therapy @RheumNow https://t.co/VJogB2otbn
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Possible new biomarker in early RA? RA patients with high level of measurable fibrogenesis (PRO-C3 serum levels) less likely to respond to TCZ, as compared to patients with low level of fibrogenesis. Abs 1986 #ACR22 @RheumNow https://t.co/xnyoV2xbWq https://t.co/Vka8UZsrar
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
@RheumNow #ACR22 https://t.co/dO7xDTApqP
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
